This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Chinese Academy of Sciences. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: The Innovative Contributions of Liangyu Jiang
Introduction
Liangyu Jiang is a prominent inventor based in Wuhan, China. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant adeno-associated viruses. His work is crucial for advancements in gene therapy and related applications.
Latest Patents
Liangyu Jiang holds a patent for a method, system, and recombinant bacmid for the preparation of recombinant adeno-associated virus. This innovative method involves several key steps: preparing a shuttle plasmid and a corresponding recombinant bacmid that includes a baculovirus genome. The shuttle plasmid contains an rAAV gene of interest flanked by inverted terminal repeats, integrated with a heterologous functional gene fragment. The recombinant bacmid includes an expression cassette of functional protein components necessary for the assembly of the rAAV. The process culminates in transfecting a host cell line with the recombinant bacmid.
Career Highlights
Liangyu Jiang is affiliated with the Chinese Academy of Sciences, where he conducts his research and development activities. His work has garnered attention for its potential applications in therapeutic settings, particularly in the treatment of genetic disorders.
Collaborations
Liangyu Jiang collaborates with notable colleagues, including Yang Wu and Zengpeng Han. Their combined expertise enhances the research output and innovation within their projects.
Conclusion
Liangyu Jiang's contributions to the field of biotechnology, particularly through his patent on recombinant adeno-associated viruses, highlight his role as an influential inventor. His work continues to pave the way for advancements in gene therapy and related fields.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
